(2024) , environ 25 % de la perte de poids totale sous analogues du GLP-1 correspondrait de la masse maigre (essentiellement du muscle), et non de la graisse
Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK (2004) New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists
Thigh Zones: Each thigh is its own zone
Simon Hughes PN D
Science Progress
Regarding combined incretin agents, the ongoing TREASURE study assesses the effects of the GLP-1/GIP receptor agonist tirzepatide on iohexol-measured GFR in people with CKD with or without diabetes (53)